ImmunoCellular Therapeutics, Ltd.(NYSE Amex Equities : IMUC)
IMUC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
Loading IMUC News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.50%||67.49||1.0%||$591.26m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.12%||365.02||2.1%||$314.21m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.15%||120.26||1.6%||$206.10m|
|KITE||Kite Pharma, Inc.||-2.46%||74.50||18.8%||$204.96m|
|ESPR||Esperion Therapeutics, Inc.||3.56%||40.40||18.7%||$170.36m|
|AUPH||Aurinia Pharmaceuticals Inc.||-1.64%||8.39||6.3%||$146.33m|
|CLVS||Clovis Oncology, Inc.||2.01%||68.53||17.5%||$144.30m|
|VRTX||Vertex Pharmaceuticals Incorporated||-1.10%||89.05||2.2%||$133.48m|
|GBT||Global Blood Therapeutics Inc||1.45%||38.55||11.9%||$106.01m|
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.